National Cancer Institute common toxicity criteria grade 3 and 4 adverse events according to the treatment actually received (except treatment-related short-term hematologic toxicities)
| Parameter . | Before randomization . | CR group (N = 105) . | Non-CR group (N = 94) . | |||
|---|---|---|---|---|---|---|
| Observation group . | ASCT group . | DHAP group . | ASCT group . | FC group . | ||
| Actually treated patients, no. | 237 | 68 | 37 | 94 | 34 | 41 |
| Hemolytic anemia | 3 | 2 | 1 | |||
| Immune thrombopenia | 1 | 1 | ||||
| Bacterial infection/aplasia | 7 | 1 | 3 | 3 | 3 | |
| Viral and fungal infections | 3 | 1 | 1 | 2 | 2 | |
| Thrombosis | 2 | |||||
| Bleeding | 2 | |||||
| Richter lymphoma | 4 | 1 | 2 | 2 | 1 | |
| Myeloma | 1 | 1 | ||||
| MDS/AML | 2 | 1 | 1 | |||
| Solid tumor | 2 | 1 | 2 | |||
| Treatment-related deaths | 7 | 1 | 3 | 2 | 2 | |
| Parameter . | Before randomization . | CR group (N = 105) . | Non-CR group (N = 94) . | |||
|---|---|---|---|---|---|---|
| Observation group . | ASCT group . | DHAP group . | ASCT group . | FC group . | ||
| Actually treated patients, no. | 237 | 68 | 37 | 94 | 34 | 41 |
| Hemolytic anemia | 3 | 2 | 1 | |||
| Immune thrombopenia | 1 | 1 | ||||
| Bacterial infection/aplasia | 7 | 1 | 3 | 3 | 3 | |
| Viral and fungal infections | 3 | 1 | 1 | 2 | 2 | |
| Thrombosis | 2 | |||||
| Bleeding | 2 | |||||
| Richter lymphoma | 4 | 1 | 2 | 2 | 1 | |
| Myeloma | 1 | 1 | ||||
| MDS/AML | 2 | 1 | 1 | |||
| Solid tumor | 2 | 1 | 2 | |||
| Treatment-related deaths | 7 | 1 | 3 | 2 | 2 | |